C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma
2 clinical trials · Condition
◉ Watch C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma
| Record | Firm | Date |
|---|---|---|
| Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas (NCT05583149) | Patrick C. Johnson, MD | 2023-03-01 |
| Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma (NCT05263583) | Cothera Bioscience, Inc | 2022-12-09 |
Track C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.